<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Valentina</forename><surname>Silvestri</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Molecular Medicine</orgName>
								<orgName type="institution" key="instit1">Sapienza University of Rome</orgName>
								<orgName type="institution" key="instit2">Viale Regina Elena</orgName>
								<address>
									<postCode>324, 00161</postCode>
									<settlement>Rome</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Molecular Medicine</orgName>
								<orgName type="institution" key="instit1">Sapienza University of Rome</orgName>
								<orgName type="institution" key="instit2">Viale Regina Elena</orgName>
								<address>
									<postCode>324, 00161</postCode>
									<settlement>Rome</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Daniel</forename><surname>Barrowdale</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Department of Public Health and Primary Care</orgName>
								<orgName type="department" key="dep2">School of Clinical Medicine</orgName>
								<orgName type="laboratory">Centre for Cancer Genetic Epidemiology</orgName>
								<orgName type="institution">University of Cambridge</orgName>
								<address>
									<settlement>Cambridge</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anna</forename><forename type="middle">Marie</forename><surname>Mulligan</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Laboratory Medicine Program</orgName>
								<orgName type="institution">University Health Network</orgName>
								<address>
									<settlement>Toronto</settlement>
									<region>ON</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Department of Laboratory Medicine and Pathobiology</orgName>
								<orgName type="institution">University of Toronto</orgName>
								<address>
									<settlement>Toronto</settlement>
									<region>ON</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Susan</forename><forename type="middle">L</forename><surname>Neuhausen</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Population Sciences</orgName>
								<orgName type="institution">Beckman Research Institute of City of Hope</orgName>
								<address>
									<settlement>Duarte</settlement>
									<region>CA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stephen</forename><surname>Fox</surname></persName>
							<affiliation key="aff6">
								<orgName type="institution">Peter MacCallum Cancer Institute</orgName>
								<address>
									<settlement>East Melbourne</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Beth</forename><forename type="middle">Y</forename><surname>Karlan</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Women&apos;s Cancer</orgName>
								<orgName type="institution">Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center</orgName>
								<address>
									<settlement>Los Angeles</settlement>
									<region>CA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gillian</forename><surname>Mitchell</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Familial Cancer Centre</orgName>
								<orgName type="institution">Peter MacCallum Cancer Centre</orgName>
								<address>
									<settlement>Melbourne</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="department">Department of Oncology</orgName>
								<orgName type="institution">The University of Melbourne</orgName>
								<address>
									<settlement>Melbourne</settlement>
									<region>VIC</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Paul</forename><surname>James</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Familial Cancer Centre</orgName>
								<orgName type="institution">Peter MacCallum Cancer Centre</orgName>
								<address>
									<settlement>Melbourne</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="department">Department of Oncology</orgName>
								<orgName type="institution">The University of Melbourne</orgName>
								<address>
									<settlement>Melbourne</settlement>
									<region>VIC</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Darcy</forename><forename type="middle">L</forename><surname>Thull</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution">University of Pittsburgh School of Medicine</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kristin</forename><forename type="middle">K</forename><surname>Zorn</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution">University of Pittsburgh School of Medicine</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Natalie</forename><forename type="middle">J</forename><surname>Carter</surname></persName>
							<affiliation key="aff11">
								<orgName type="institution">UPMC Cancer Center</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Katherine</forename><forename type="middle">L</forename><surname>Nathanson</surname></persName>
							<affiliation key="aff12">
								<orgName type="department" key="dep1">Department of Medicine</orgName>
								<orgName type="department" key="dep2">Abramson Cancer Center</orgName>
							</affiliation>
							<affiliation key="aff13">
								<orgName type="department">Perelman School of Medicine</orgName>
								<orgName type="institution">The University of Pennsylvania</orgName>
								<address>
									<settlement>Philadelphia</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Susan</forename><forename type="middle">M</forename><surname>Domchek</surname></persName>
							<affiliation key="aff12">
								<orgName type="department" key="dep1">Department of Medicine</orgName>
								<orgName type="department" key="dep2">Abramson Cancer Center</orgName>
							</affiliation>
							<affiliation key="aff13">
								<orgName type="department">Perelman School of Medicine</orgName>
								<orgName type="institution">The University of Pennsylvania</orgName>
								<address>
									<settlement>Philadelphia</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Timothy</forename><forename type="middle">R</forename><surname>Rebbeck</surname></persName>
							<affiliation key="aff14">
								<orgName type="department" key="dep1">Department of Epidemiology and Biostatistics</orgName>
								<orgName type="department" key="dep2">Perelman School of Medicine</orgName>
								<orgName type="institution" key="instit1">Abramson Cancer Center</orgName>
								<orgName type="institution" key="instit2">University of Pennsylvania</orgName>
								<address>
									<settlement>Philadelphia</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Susan</forename><forename type="middle">J</forename><surname>Ramus</surname></persName>
							<affiliation key="aff15">
								<orgName type="department" key="dep1">Department of Preventive Medicine</orgName>
								<orgName type="department" key="dep2">Keck School of Medicine</orgName>
								<orgName type="institution">University of Southern California Norris Comprehensive Cancer Center</orgName>
								<address>
									<settlement>Los Angeles</settlement>
									<region>CA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Robert</forename><forename type="middle">L</forename><surname>Nussbaum</surname></persName>
							<affiliation key="aff16">
								<orgName type="department">Department of Medicine and Genetics</orgName>
								<orgName type="institution">University of California</orgName>
								<address>
									<settlement>San Francisco, San Francisco</settlement>
									<region>CA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Olufunmilayo</forename><forename type="middle">I</forename><surname>Olopade</surname></persName>
							<affiliation key="aff17">
								<orgName type="department">Center for Clinical Cancer Genetics and Global Health</orgName>
								<orgName type="institution">University of Chicago Medical Center</orgName>
								<address>
									<settlement>Chicago</settlement>
									<region>IL</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Johanna</forename><surname>Rantala</surname></persName>
							<affiliation key="aff18">
								<orgName type="department">Department of Clinical Genetics</orgName>
								<orgName type="institution">Karolinska University Hospital</orgName>
								<address>
									<settlement>Stockholm</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sook-Yee</forename><surname>Yoon</surname></persName>
							<affiliation key="aff19">
								<orgName type="department">Sime Darby Medical Centre</orgName>
								<orgName type="institution">Cancer Research Initiatives Foundation</orgName>
								<address>
									<addrLine>Subang Jaya</addrLine>
									<country key="MY">Malaysia</country>
								</address>
							</affiliation>
							<affiliation key="aff20">
								<orgName type="department">Faculty of Medicine</orgName>
								<orgName type="institution" key="instit1">University Malaya Cancer Research Institute</orgName>
								<orgName type="institution" key="instit2">University Malaya Medical Centre</orgName>
								<address>
									<addrLine>University Malaya</addrLine>
									<settlement>Kuala Lumpur</settlement>
									<country key="MY">Malaysia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Maria</forename><forename type="middle">A</forename><surname>Caligo</surname></persName>
							<affiliation key="aff21">
								<orgName type="department">Department of Laboratory Medicine</orgName>
								<orgName type="institution" key="instit1">Section of Genetic Oncology</orgName>
								<orgName type="institution" key="instit2">University of Pisa and University Hospital of Pisa</orgName>
								<address>
									<settlement>Pisa</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Laura</forename><surname>Spugnesi</surname></persName>
							<affiliation key="aff21">
								<orgName type="department">Department of Laboratory Medicine</orgName>
								<orgName type="institution" key="instit1">Section of Genetic Oncology</orgName>
								<orgName type="institution" key="instit2">University of Pisa and University Hospital of Pisa</orgName>
								<address>
									<settlement>Pisa</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anders</forename><surname>Bojesen</surname></persName>
							<affiliation key="aff22">
								<orgName type="department">Department of Clinical Genetics</orgName>
								<orgName type="institution">Vejle Hospital</orgName>
								<address>
									<settlement>Vejle</settlement>
									<country key="DK">Denmark</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Inge</forename><surname>Sokilde Pedersen</surname></persName>
							<affiliation key="aff23">
								<orgName type="department">Section of Molecular Diagnostics</orgName>
							</affiliation>
							<affiliation key="aff24">
								<orgName type="department">Department of Biochemistry</orgName>
								<orgName type="institution">Aalborg University Hospital</orgName>
								<address>
									<settlement>Aalborg</settlement>
									<country key="DK">Denmark</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mads</forename><surname>Thomassen</surname></persName>
							<affiliation key="aff25">
								<orgName type="department">Department of Clinical Genetics</orgName>
								<orgName type="institution">Odense University Hospital</orgName>
								<address>
									<settlement>Odense C</settlement>
									<country key="DK">Denmark</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Uffe</forename><surname>Birk Jensen</surname></persName>
							<affiliation key="aff26">
								<orgName type="department">Department of Clinical Genetics</orgName>
								<orgName type="institution">Aarhus University Hospital</orgName>
								<address>
									<settlement>Aarhus N</settlement>
									<country key="DK">Denmark</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Amanda</forename><forename type="middle">Ewart</forename><surname>Toland</surname></persName>
							<affiliation key="aff27">
								<orgName type="department" key="dep1">Department of Molecular Virology, Immunology and Medical Genetics</orgName>
								<orgName type="department" key="dep2">College of Medicine</orgName>
								<orgName type="institution">The Ohio State University</orgName>
								<address>
									<settlement>Columbus</settlement>
									<region>OH</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Leigha</forename><surname>Senter</surname></persName>
							<affiliation key="aff28">
								<orgName type="department">Department of Internal Medicine</orgName>
								<orgName type="laboratory">Division of Human Genetics</orgName>
								<orgName type="institution" key="instit1">The Comprehensive Cancer Center</orgName>
								<orgName type="institution" key="instit2">The Ohio State University</orgName>
								<address>
									<settlement>Columbus</settlement>
									<region>OH</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Irene</forename><forename type="middle">L</forename><surname>Andrulis</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Laboratory Medicine and Pathobiology</orgName>
								<orgName type="institution">University of Toronto</orgName>
								<address>
									<settlement>Toronto</settlement>
									<region>ON</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
							<affiliation key="aff29">
								<orgName type="institution" key="instit1">Lunenfeld-Tanenbaum Research Institute</orgName>
								<orgName type="institution" key="instit2">Mount Sinai Hospital</orgName>
								<address>
									<settlement>Toronto</settlement>
									<region>ON</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
							<affiliation key="aff30">
								<orgName type="department">Department of Molecular Genetics</orgName>
								<orgName type="institution">University of Toronto</orgName>
								<address>
									<settlement>Toronto</settlement>
									<region>ON</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gord</forename><surname>Glendon</surname></persName>
							<affiliation key="aff29">
								<orgName type="institution" key="instit1">Lunenfeld-Tanenbaum Research Institute</orgName>
								<orgName type="institution" key="instit2">Mount Sinai Hospital</orgName>
								<address>
									<settlement>Toronto</settlement>
									<region>ON</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Peter</forename><forename type="middle">J</forename><surname>Hulick</surname></persName>
							<affiliation key="aff31">
								<orgName type="department" key="dep1">Center for Medical Genetics</orgName>
								<orgName type="department" key="dep2">30 N.N. Petrov Institute of Oncology</orgName>
								<orgName type="institution">North Shore University Health System</orgName>
								<address>
									<settlement>Evanston, St. Petersburg</settlement>
									<region>IL</region>
									<country>USA., Russia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Evgeny</forename><forename type="middle">N</forename><surname>Imyanitov</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Mark</forename><forename type="middle">H</forename><surname>Greene</surname></persName>
							<affiliation key="aff32">
								<orgName type="department" key="dep1">Clinical Genetics Branch</orgName>
								<orgName type="department" key="dep2">Division of Cancer Epidemiology and Genetics</orgName>
								<orgName type="institution" key="instit1">National Cancer Institute</orgName>
								<orgName type="institution" key="instit2">National Institutes of Health</orgName>
								<address>
									<settlement>Rockville</settlement>
									<region>MD</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Phuong</forename><forename type="middle">L</forename><surname>Mai</surname></persName>
							<affiliation key="aff32">
								<orgName type="department" key="dep1">Clinical Genetics Branch</orgName>
								<orgName type="department" key="dep2">Division of Cancer Epidemiology and Genetics</orgName>
								<orgName type="institution" key="instit1">National Cancer Institute</orgName>
								<orgName type="institution" key="instit2">National Institutes of Health</orgName>
								<address>
									<settlement>Rockville</settlement>
									<region>MD</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christian</forename><forename type="middle">F</forename><surname>Singer</surname></persName>
							<affiliation key="aff33">
								<orgName type="department" key="dep1">Department of Obstetrics and Gynecology</orgName>
								<orgName type="department" key="dep2">Comprehensive Cancer Center</orgName>
								<orgName type="institution">Medical University of Vienna</orgName>
								<address>
									<settlement>Vienna</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christine</forename><surname>Rappaport-Fuerhauser</surname></persName>
							<affiliation key="aff33">
								<orgName type="department" key="dep1">Department of Obstetrics and Gynecology</orgName>
								<orgName type="department" key="dep2">Comprehensive Cancer Center</orgName>
								<orgName type="institution">Medical University of Vienna</orgName>
								<address>
									<settlement>Vienna</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gero</forename><surname>Kramer</surname></persName>
							<affiliation key="aff34">
								<orgName type="department">Department of Urology</orgName>
								<orgName type="institution">Medical University of Vienna</orgName>
								<address>
									<settlement>Vienna</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Joseph</forename><surname>Vijai</surname></persName>
							<affiliation key="aff35">
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="institution">Memorial Sloan-Kettering Cancer Center</orgName>
								<address>
									<settlement>New York</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kenneth</forename><surname>Offit</surname></persName>
							<affiliation key="aff35">
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="institution">Memorial Sloan-Kettering Cancer Center</orgName>
								<address>
									<settlement>New York</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mark</forename><surname>Robson</surname></persName>
							<affiliation key="aff36">
								<orgName type="department" key="dep1">Clinical Genetics Service</orgName>
								<orgName type="department" key="dep2">Department of Medicine</orgName>
								<orgName type="institution">Memorial Sloan-Kettering Cancer Center</orgName>
								<address>
									<settlement>New York</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anne</forename><surname>Lincoln</surname></persName>
							<affiliation key="aff35">
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="institution">Memorial Sloan-Kettering Cancer Center</orgName>
								<address>
									<settlement>New York</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Lauren</forename><surname>Jacobs</surname></persName>
							<affiliation key="aff35">
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="institution">Memorial Sloan-Kettering Cancer Center</orgName>
								<address>
									<settlement>New York</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Eva</forename><surname>Machackova</surname></persName>
							<affiliation key="aff37">
								<orgName type="department">Department of Cancer Epidemiology and Genetics</orgName>
								<orgName type="institution">Masaryk Memorial Cancer Institute</orgName>
								<address>
									<settlement>Brno</settlement>
									<country key="CZ">Czech Republic</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Lenka</forename><surname>Foretova</surname></persName>
							<affiliation key="aff38">
								<orgName type="department">Masaryk Memorial Cancer Institute and Faculty of Medicine</orgName>
								<orgName type="institution">Masaryk University</orgName>
								<address>
									<settlement>Brno</settlement>
									<country key="CZ">Czech Republic</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Marie</forename><surname>Navratilova</surname></persName>
							<affiliation key="aff37">
								<orgName type="department">Department of Cancer Epidemiology and Genetics</orgName>
								<orgName type="institution">Masaryk Memorial Cancer Institute</orgName>
								<address>
									<settlement>Brno</settlement>
									<country key="CZ">Czech Republic</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Petra</forename><surname>Vasickova</surname></persName>
							<affiliation key="aff37">
								<orgName type="department">Department of Cancer Epidemiology and Genetics</orgName>
								<orgName type="institution">Masaryk Memorial Cancer Institute</orgName>
								<address>
									<settlement>Brno</settlement>
									<country key="CZ">Czech Republic</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Fergus</forename><forename type="middle">J</forename><surname>Couch</surname></persName>
							<affiliation key="aff39">
								<orgName type="department">Department of Laboratory Medicine and Pathology</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<settlement>Rochester</settlement>
									<region>MN</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff40">
								<orgName type="department">Department of Health Sciences Research</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<settlement>Rochester</settlement>
									<region>MN</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Emily</forename><surname>Hallberg</surname></persName>
							<affiliation key="aff40">
								<orgName type="department">Department of Health Sciences Research</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<settlement>Rochester</settlement>
									<region>MN</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kathryn</forename><forename type="middle">J</forename><surname>Ruddy</surname></persName>
							<affiliation key="aff41">
								<orgName type="department">Department of Oncology</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<settlement>Rochester</settlement>
									<region>MN</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Priyanka</forename><surname>Sharma</surname></persName>
							<affiliation key="aff42">
								<orgName type="department">Department of Hematology and Oncology</orgName>
								<orgName type="institution">University of Kansas Medical Center</orgName>
								<address>
									<settlement>Kansas City</settlement>
									<region>KS</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sung-Won</forename><surname>Kim</surname></persName>
							<affiliation key="aff43">
								<orgName type="department">Department of Surgery</orgName>
								<orgName type="institution">Daerim St. Mary&apos;s Hospital</orgName>
								<address>
									<settlement>Seoul</settlement>
									<country key="KR">Korea</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Manuel</forename><forename type="middle">R</forename><surname>Investigators</surname></persName>
						</author>
						<author>
							<persName><surname>Teixeira</surname></persName>
							<affiliation key="aff44">
								<orgName type="department">Department of Genetics</orgName>
								<orgName type="institution">Portuguese Institute of Oncology</orgName>
								<address>
									<settlement>Porto</settlement>
									<country key="PT">Portugal</country>
								</address>
							</affiliation>
							<affiliation key="aff45">
								<orgName type="department">Biomedical Sciences Institute (ICBAS)</orgName>
								<orgName type="institution">University of Porto</orgName>
								<address>
									<settlement>Porto</settlement>
									<country key="PT">Portugal</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Pedro</forename><surname>Pinto</surname></persName>
							<affiliation key="aff44">
								<orgName type="department">Department of Genetics</orgName>
								<orgName type="institution">Portuguese Institute of Oncology</orgName>
								<address>
									<settlement>Porto</settlement>
									<country key="PT">Portugal</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Marco</forename><surname>Montagna</surname></persName>
							<affiliation key="aff46">
								<orgName type="laboratory">Immunology and Molecular Oncology Unit</orgName>
								<orgName type="institution">Veneto Institute of Oncology IOV -IRCCS (Scientific Institute of Hospitalization and Care)</orgName>
								<address>
									<settlement>Padua</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Laura</forename><surname>Matricardi</surname></persName>
							<affiliation key="aff46">
								<orgName type="laboratory">Immunology and Molecular Oncology Unit</orgName>
								<orgName type="institution">Veneto Institute of Oncology IOV -IRCCS (Scientific Institute of Hospitalization and Care)</orgName>
								<address>
									<settlement>Padua</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Adalgeir</forename><surname>Arason</surname></persName>
							<affiliation key="aff47">
								<orgName type="department" key="dep1">Department of Pathology</orgName>
								<orgName type="department" key="dep2">Faculty of Medicine</orgName>
								<orgName type="institution" key="instit1">Landspitali University Hospital and Biomedical Centre (BMC)</orgName>
								<orgName type="institution" key="instit2">University of Iceland</orgName>
								<address>
									<settlement>Reykjavik</settlement>
									<country key="IS">Iceland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Oskar</forename><forename type="middle">Th</forename><surname>Johannsson</surname></persName>
							<affiliation key="aff48">
								<orgName type="department" key="dep1">Department of Oncology</orgName>
								<orgName type="department" key="dep2">Faculty of Medicine</orgName>
								<orgName type="institution" key="instit1">Landspitali University Hospital</orgName>
								<orgName type="institution" key="instit2">University of Iceland</orgName>
								<address>
									<settlement>Reykjavik</settlement>
									<country key="IS">Iceland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rosa</forename><forename type="middle">B</forename><surname>Barkardottir</surname></persName>
							<affiliation key="aff47">
								<orgName type="department" key="dep1">Department of Pathology</orgName>
								<orgName type="department" key="dep2">Faculty of Medicine</orgName>
								<orgName type="institution" key="instit1">Landspitali University Hospital and Biomedical Centre (BMC)</orgName>
								<orgName type="institution" key="instit2">University of Iceland</orgName>
								<address>
									<settlement>Reykjavik</settlement>
									<country key="IS">Iceland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anna</forename><surname>Jakubowska</surname></persName>
							<affiliation key="aff49">
								<orgName type="department">Department of Genetics and Pathology</orgName>
								<orgName type="institution">Pomeranian Medical University</orgName>
								<address>
									<settlement>Szczecin</settlement>
									<country key="PL">Poland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jan</forename><surname>Lubinski</surname></persName>
							<affiliation key="aff49">
								<orgName type="department">Department of Genetics and Pathology</orgName>
								<orgName type="institution">Pomeranian Medical University</orgName>
								<address>
									<settlement>Szczecin</settlement>
									<country key="PL">Poland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Angel</forename><surname>Izquierdo</surname></persName>
							<affiliation key="aff50">
								<orgName type="department">Biomedical Research Institute of Girona (IDIBGI)</orgName>
								<orgName type="laboratory">Genetic Counseling Unit, Hereditary Cancer Program</orgName>
								<orgName type="institution">Catalan Institute of Oncology</orgName>
								<address>
									<settlement>Girona</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Miguel</forename><forename type="middle">Angel</forename><surname>Pujana</surname></persName>
							<affiliation key="aff51">
								<orgName type="laboratory">Breast Cancer and Systems Biology Unit</orgName>
								<orgName type="institution" key="instit1">Bellvitge Biomedical Research Institute (IDIBELL)</orgName>
								<orgName type="institution" key="instit2">Catalan Institute of Oncology</orgName>
								<address>
									<settlement>Barcelona</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Judith</forename><surname>Balmaña</surname></persName>
							<affiliation key="aff52">
								<orgName type="department">Department of Medical Oncology</orgName>
								<orgName type="institution">Vall d&apos;Hebron University Hospital</orgName>
								<address>
									<settlement>Barcelona</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Orland</forename><surname>Diez</surname></persName>
							<affiliation key="aff53">
								<orgName type="department">Institute of Oncology (VHIO)</orgName>
								<orgName type="institution">Oncogenetics Group, Vall d&apos;Hebron University Hospital</orgName>
								<address>
									<addrLine>Vall d&apos;Hebron</addrLine>
								</address>
							</affiliation>
							<affiliation key="aff54">
								<orgName type="institution">Universitat Autònoma de Barcelona</orgName>
								<address>
									<settlement>Barcelona</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gabriella</forename><surname>Ivady</surname></persName>
							<affiliation key="aff55">
								<orgName type="department">Department of Pathology</orgName>
								<orgName type="institution">National Institute of Oncology</orgName>
								<address>
									<settlement>Budapest</settlement>
									<country key="HU">Hungary</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Janos</forename><surname>Papp</surname></persName>
							<affiliation key="aff56">
								<orgName type="department">Department of Molecular Genetics</orgName>
								<orgName type="institution">National Institute of Oncology</orgName>
								<address>
									<settlement>Budapest</settlement>
									<country key="HU">Hungary</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Edith</forename><surname>Olah</surname></persName>
							<affiliation key="aff56">
								<orgName type="department">Department of Molecular Genetics</orgName>
								<orgName type="institution">National Institute of Oncology</orgName>
								<address>
									<settlement>Budapest</settlement>
									<country key="HU">Hungary</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ava</forename><surname>Kwong</surname></persName>
							<affiliation key="aff57">
								<orgName type="department">Cancer Genetics Center</orgName>
								<orgName type="institution" key="instit1">The Hong Kong Hereditary Breast Cancer Family Registry</orgName>
								<orgName type="institution" key="instit2">Hong Kong Sanatorium and Hospital</orgName>
								<address>
									<settlement>Hong Kong</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff58">
								<orgName type="department">Department of Surgery</orgName>
								<orgName type="institution">The University of Hong Kong</orgName>
								<address>
									<settlement>Hong Kong</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>Hereditary Breast</roleName><forename type="first">Ovarian</forename><forename type="middle">Cancer</forename><surname>Research</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Group</forename><surname>Netherlands</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Heli</forename><surname>Nevanlinna</surname></persName>
							<affiliation key="aff59">
								<orgName type="department">Department of Obstetrics and Gynecology</orgName>
								<orgName type="institution">University of Helsinki and Helsinki University Hospital</orgName>
								<address>
									<settlement>Helsinki</settlement>
									<country key="FI">Finland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kristiina</forename><surname>Aittomäki</surname></persName>
							<affiliation key="aff60">
								<orgName type="department">Department of Clinical Genetics</orgName>
								<orgName type="institution">University of Helsinki and Helsinki University Hospital</orgName>
								<address>
									<settlement>Helsinki</settlement>
									<country key="FI">Finland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Pedro</forename><forename type="middle">Perez</forename><surname>Segura</surname></persName>
							<affiliation key="aff61">
								<orgName type="department">Department of Oncology</orgName>
								<orgName type="institution" key="instit1">San Carlos Clinical Hospital Health Research Institute (IdISSC)</orgName>
								<orgName type="institution" key="instit2">San Carlos Clinical Hospital</orgName>
								<address>
									<settlement>Madrid</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Trinidad</forename><surname>Caldes</surname></persName>
							<affiliation key="aff62">
								<orgName type="laboratory">Molecular Oncology Laboratory</orgName>
								<orgName type="institution" key="instit1">San Carlos Clinical Hospital Health Research Institute (IdISSC)</orgName>
								<orgName type="institution" key="instit2">San Carlos Clinical Hospital</orgName>
								<address>
									<settlement>Madrid</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Tom</forename><surname>Van Maerken</surname></persName>
							<affiliation key="aff63">
								<orgName type="department">Center for Medical Genetics</orgName>
								<orgName type="institution">Ghent University</orgName>
								<address>
									<settlement>Ghent</settlement>
									<country>Belgium. 62 Lombardi</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bruce</forename><surname>Poppe</surname></persName>
							<affiliation key="aff63">
								<orgName type="department">Center for Medical Genetics</orgName>
								<orgName type="institution">Ghent University</orgName>
								<address>
									<settlement>Ghent</settlement>
									<country>Belgium. 62 Lombardi</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kathleen</forename><forename type="middle">B M</forename><surname>Claes</surname></persName>
							<affiliation key="aff63">
								<orgName type="department">Center for Medical Genetics</orgName>
								<orgName type="institution">Ghent University</orgName>
								<address>
									<settlement>Ghent</settlement>
									<country>Belgium. 62 Lombardi</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Claudine</forename><surname>Isaacs</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Camille</forename><surname>Elan</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Christine</forename><surname>Lasset</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Dominique</forename><surname>Stoppa-Lyonnet</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Laure</forename><surname>Barjhoux</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Muriel</forename><surname>Belotti</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Alfons</forename><surname>Meindl</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Andrea</forename><surname>Gehrig</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Christian</forename><surname>Sutter</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Christoph</forename><surname>Engel</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Dieter</forename><surname>Niederacher</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Doris</forename><surname>Steinemann</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Eric</forename><surname>Hahnen</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Karin</forename><surname>Kast</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Norbert</forename><surname>Arnold</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Raymonda</forename><surname>Varon-Mateeva</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Dorothea</forename><surname>Wand</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Andrew</forename><forename type="middle">K</forename><surname>Godwin</surname></persName>
						</author>
						<author>
							<persName><forename type="first">D</forename><surname>Gareth Evans</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Debra</forename><surname>Frost</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Department of Public Health and Primary Care</orgName>
								<orgName type="department" key="dep2">School of Clinical Medicine</orgName>
								<orgName type="laboratory">Centre for Cancer Genetic Epidemiology</orgName>
								<orgName type="institution">University of Cambridge</orgName>
								<address>
									<settlement>Cambridge</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jo</forename><surname>Perkins</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Department of Public Health and Primary Care</orgName>
								<orgName type="department" key="dep2">School of Clinical Medicine</orgName>
								<orgName type="laboratory">Centre for Cancer Genetic Epidemiology</orgName>
								<orgName type="institution">University of Cambridge</orgName>
								<address>
									<settlement>Cambridge</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Julian</forename><surname>Adlard</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Louise</forename><surname>Izatt</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Radka</forename><surname>Platte</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ros</forename><surname>Eeles</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Steve</forename><surname>Ellis</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Department of Public Health and Primary Care</orgName>
								<orgName type="department" key="dep2">School of Clinical Medicine</orgName>
								<orgName type="laboratory">Centre for Cancer Genetic Epidemiology</orgName>
								<orgName type="institution">University of Cambridge</orgName>
								<address>
									<settlement>Cambridge</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ute</forename><surname>Hamann</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Judy</forename><surname>Garber</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Florentia</forename><surname>Fostira</surname></persName>
						</author>
						<author>
							<persName><forename type="first">George</forename><surname>Fountzilas</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Barbara</forename><surname>Pasini</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Giuseppe</forename><surname>Giannini</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Molecular Medicine</orgName>
								<orgName type="institution" key="instit1">Sapienza University of Rome</orgName>
								<orgName type="institution" key="instit2">Viale Regina Elena</orgName>
								<address>
									<postCode>324, 00161</postCode>
									<settlement>Rome</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Molecular Medicine</orgName>
								<orgName type="institution" key="instit1">Sapienza University of Rome</orgName>
								<orgName type="institution" key="instit2">Viale Regina Elena</orgName>
								<address>
									<postCode>324, 00161</postCode>
									<settlement>Rome</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Piera</forename><surname>Rizzolo</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Molecular Medicine</orgName>
								<orgName type="institution" key="instit1">Sapienza University of Rome</orgName>
								<orgName type="institution" key="instit2">Viale Regina Elena</orgName>
								<address>
									<postCode>324, 00161</postCode>
									<settlement>Rome</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Molecular Medicine</orgName>
								<orgName type="institution" key="instit1">Sapienza University of Rome</orgName>
								<orgName type="institution" key="instit2">Viale Regina Elena</orgName>
								<address>
									<postCode>324, 00161</postCode>
									<settlement>Rome</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Antonio</forename><surname>Russo</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Laura</forename><surname>Cortesi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Laura</forename><surname>Papi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Liliana</forename><surname>Varesco</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Domenico</forename><surname>Palli</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ines</forename><surname>Zanna</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Antonella</forename><surname>Savarese</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Paolo</forename><surname>Radice</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Siranoush</forename><surname>Manoukian</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Bernard</forename><surname>Peissel</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Monica</forename><surname>Barile</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Bernardo</forename><surname>Bonanni</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Alessandra</forename><surname>Viel</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Valeria</forename><surname>Pensotti</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution">University of Pittsburgh School of Medicine</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stefania</forename><surname>Tommasi</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution">University of Pittsburgh School of Medicine</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Paolo</forename><surname>Peterlongo</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution">University of Pittsburgh School of Medicine</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jeffrey</forename><forename type="middle">N</forename><surname>Weitzel</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution">University of Pittsburgh School of Medicine</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ana</forename><surname>Osorio</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution">University of Pittsburgh School of Medicine</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Javier</forename><surname>Benitez</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution">University of Pittsburgh School of Medicine</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Lesley</forename><surname>Mcguffog</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Department of Public Health and Primary Care</orgName>
								<orgName type="department" key="dep2">School of Clinical Medicine</orgName>
								<orgName type="laboratory">Centre for Cancer Genetic Epidemiology</orgName>
								<orgName type="institution">University of Cambridge</orgName>
								<address>
									<settlement>Cambridge</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="institution">University of Pittsburgh School of Medicine</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sue</forename><surname>Healey</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution">University of Pittsburgh School of Medicine</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anne-Marie</forename><surname>Gerdes</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution">University of Pittsburgh School of Medicine</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff11">
								<orgName type="institution">UPMC Cancer Center</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Thomas</forename><forename type="middle">V O</forename><surname>Hansen</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution">University of Pittsburgh School of Medicine</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff11">
								<orgName type="institution">UPMC Cancer Center</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Linda</forename><surname>Steele</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Population Sciences</orgName>
								<orgName type="institution">Beckman Research Institute of City of Hope</orgName>
								<address>
									<settlement>Duarte</settlement>
									<region>CA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="institution">University of Pittsburgh School of Medicine</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff11">
								<orgName type="institution">UPMC Cancer Center</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Yuan</forename><forename type="middle">Chun</forename><surname>Ding</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Population Sciences</orgName>
								<orgName type="institution">Beckman Research Institute of City of Hope</orgName>
								<address>
									<settlement>Duarte</settlement>
									<region>CA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="institution">University of Pittsburgh School of Medicine</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Nadine</forename><surname>Tung</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution">University of Pittsburgh School of Medicine</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff11">
								<orgName type="institution">UPMC Cancer Center</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff12">
								<orgName type="department" key="dep1">Department of Medicine</orgName>
								<orgName type="department" key="dep2">Abramson Cancer Center</orgName>
							</affiliation>
							<affiliation key="aff13">
								<orgName type="department">Perelman School of Medicine</orgName>
								<orgName type="institution">The University of Pennsylvania</orgName>
								<address>
									<settlement>Philadelphia</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ramunas</forename><surname>Janavicius</surname></persName>
							<affiliation key="aff11">
								<orgName type="institution">UPMC Cancer Center</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff14">
								<orgName type="department" key="dep1">Department of Epidemiology and Biostatistics</orgName>
								<orgName type="department" key="dep2">Perelman School of Medicine</orgName>
								<orgName type="institution" key="instit1">Abramson Cancer Center</orgName>
								<orgName type="institution" key="instit2">University of Pennsylvania</orgName>
								<address>
									<settlement>Philadelphia</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">David</forename><forename type="middle">E</forename><surname>Goldgar</surname></persName>
							<affiliation key="aff11">
								<orgName type="institution">UPMC Cancer Center</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff15">
								<orgName type="department" key="dep1">Department of Preventive Medicine</orgName>
								<orgName type="department" key="dep2">Keck School of Medicine</orgName>
								<orgName type="institution">University of Southern California Norris Comprehensive Cancer Center</orgName>
								<address>
									<settlement>Los Angeles</settlement>
									<region>CA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Saundra</forename><forename type="middle">S</forename><surname>Buys</surname></persName>
							<affiliation key="aff11">
								<orgName type="institution">UPMC Cancer Center</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff16">
								<orgName type="department">Department of Medicine and Genetics</orgName>
								<orgName type="institution">University of California</orgName>
								<address>
									<settlement>San Francisco, San Francisco</settlement>
									<region>CA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mary</forename><forename type="middle">B</forename><surname>Daly</surname></persName>
							<affiliation key="aff11">
								<orgName type="institution">UPMC Cancer Center</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff17">
								<orgName type="department">Center for Clinical Cancer Genetics and Global Health</orgName>
								<orgName type="institution">University of Chicago Medical Center</orgName>
								<address>
									<settlement>Chicago</settlement>
									<region>IL</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anita</forename><surname>Bane</surname></persName>
							<affiliation key="aff11">
								<orgName type="institution">UPMC Cancer Center</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff18">
								<orgName type="department">Department of Clinical Genetics</orgName>
								<orgName type="institution">Karolinska University Hospital</orgName>
								<address>
									<settlement>Stockholm</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mary</forename><forename type="middle">Beth</forename><surname>Terry</surname></persName>
							<affiliation key="aff11">
								<orgName type="institution">UPMC Cancer Center</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff19">
								<orgName type="department">Sime Darby Medical Centre</orgName>
								<orgName type="institution">Cancer Research Initiatives Foundation</orgName>
								<address>
									<addrLine>Subang Jaya</addrLine>
									<country key="MY">Malaysia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Esther</forename><forename type="middle">M</forename><surname>John</surname></persName>
							<affiliation key="aff11">
								<orgName type="institution">UPMC Cancer Center</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff20">
								<orgName type="department">Faculty of Medicine</orgName>
								<orgName type="institution" key="instit1">University Malaya Cancer Research Institute</orgName>
								<orgName type="institution" key="instit2">University Malaya Medical Centre</orgName>
								<address>
									<addrLine>University Malaya</addrLine>
									<settlement>Kuala Lumpur</settlement>
									<country key="MY">Malaysia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Melissa</forename><surname>Southey</surname></persName>
							<affiliation key="aff12">
								<orgName type="department" key="dep1">Department of Medicine</orgName>
								<orgName type="department" key="dep2">Abramson Cancer Center</orgName>
							</affiliation>
							<affiliation key="aff13">
								<orgName type="department">Perelman School of Medicine</orgName>
								<orgName type="institution">The University of Pennsylvania</orgName>
								<address>
									<settlement>Philadelphia</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff21">
								<orgName type="department">Department of Laboratory Medicine</orgName>
								<orgName type="institution" key="instit1">Section of Genetic Oncology</orgName>
								<orgName type="institution" key="instit2">University of Pisa and University Hospital of Pisa</orgName>
								<address>
									<settlement>Pisa</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Douglas</forename><forename type="middle">F</forename><surname>Easton</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Department of Public Health and Primary Care</orgName>
								<orgName type="department" key="dep2">School of Clinical Medicine</orgName>
								<orgName type="laboratory">Centre for Cancer Genetic Epidemiology</orgName>
								<orgName type="institution">University of Cambridge</orgName>
								<address>
									<settlement>Cambridge</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Georgia</forename><surname>Chenevix-Trench</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution">University of Pittsburgh School of Medicine</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Antonis</forename><forename type="middle">C</forename><surname>Antoniou</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Department of Public Health and Primary Care</orgName>
								<orgName type="department" key="dep2">School of Clinical Medicine</orgName>
								<orgName type="laboratory">Centre for Cancer Genetic Epidemiology</orgName>
								<orgName type="institution">University of Cambridge</orgName>
								<address>
									<settlement>Cambridge</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Laura</forename><surname>Ottini</surname></persName>
							<email>laura.ottini@uniroma1.it</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Molecular Medicine</orgName>
								<orgName type="institution" key="instit1">Sapienza University of Rome</orgName>
								<orgName type="institution" key="instit2">Viale Regina Elena</orgName>
								<address>
									<postCode>324, 00161</postCode>
									<settlement>Rome</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Molecular Medicine</orgName>
								<orgName type="institution" key="instit1">Sapienza University of Rome</orgName>
								<orgName type="institution" key="instit2">Viale Regina Elena</orgName>
								<address>
									<postCode>324, 00161</postCode>
									<settlement>Rome</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">C0FA66DF98D05415FFADD991A1858178</idno>
					<idno type="DOI">10.1186/s13058-016-0671-y</idno>
					<note type="submission">Received: 28 September 2015 Accepted: 6 January 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:30+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Male breast cancer</term>
					<term>BRCA1/2</term>
					<term>Pathology</term>
					<term>Histologic grade</term>
					<term>Genotype-phenotype correlations</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background: BRCA1 and, more commonly, BRCA2 mutations are associated with increased risk of male breast cancer (MBC).</s><s>However, only a paucity of data exists on the pathology of breast cancers (BCs) in men with BRCA1/2 mutations.</s><s>Using the largest available dataset, we determined whether MBCs arising in BRCA1/2 mutation carriers display specific pathologic features and whether these features differ from those of BRCA1/2 female BCs (FBCs).</s></p><p><s>Methods: We characterised the pathologic features of 419 BRCA1/2 MBCs and, using logistic regression analysis, contrasted those with data from 9675 BRCA1/2 FBCs and with population-based data from 6351 MBCs in the Surveillance, Epidemiology, and End Results (SEER) database.</s></p><p><s>Results: Among BRCA2 MBCs, grade significantly decreased with increasing age at diagnosis (P = 0.005).</s><s>Compared with BRCA2 FBCs, BRCA2 MBCs were of significantly higher stage (P for trend = 2 × 10 −5 ) and higher grade (P for trend = 0.005) and were more likely to be oestrogen receptor-positive [odds ratio (OR) 10.59; 95 % confidence interval (CI) 5.15-21.80]</s><s>and progesterone receptor-positive (OR 5.04;.</s><s>With the exception of grade, similar patterns of associations emerged when we compared BRCA1 MBCs and FBCs.</s><s>BRCA2 MBCs also presented with higher grade than MBCs from the SEER database (P for trend = 4 × 10 −12 ).</s></p><p><s>Conclusions: On the basis of the largest series analysed to date, our results show that BRCA1/2 MBCs display distinct pathologic characteristics compared with BRCA1/2 FBCs, and we identified a specific BRCA2-associated MBC phenotype characterised by a variable suggesting greater biological aggressiveness (i.e., high histologic grade).</s><s>These findings could lead to the development of gender-specific risk prediction models and guide clinical strategies appropriate for MBC management.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Background</head><p><s>Male breast cancer (MBC) is a rare disease.</s><s>It accounts for less than 1 % of all breast cancers and less than 1 % of all cancers in men.</s><s>The annual incidence is estimated at about 1 per 100,000 men worldwide <ref type="bibr" target="#b9">[1]</ref>, and lifetime risk is less than 1 in 1000.</s><s>Incidence rates for MBC increase linearly and steadily with age, with the mean age at diagnosis being between 60 and 70 years <ref type="bibr" target="#b10">[2]</ref>.</s><s>Family history of breast cancer is an important risk factor for developing MBC, suggesting the importance of genetic factors in MBC susceptibility <ref type="bibr" target="#b11">[3,</ref><ref type="bibr" target="#b12">4]</ref>.</s><s>Mutations in the two major high-penetrance breast cancer genes, BRCA1 (breast cancer 1, early onset gene) and predominantly BRCA2 (breast cancer 2, early onset gene), account for approximately 10 % of MBCs outside populations with BRCA founder mutations <ref type="bibr" target="#b13">[5]</ref>.</s><s>The lifetime risk of developing MBC has been estimated to be in the range of 1-5 % for BRCA1 and 5-10 % for BRCA2 mutation carriers, compared with a risk of 0.1 % in the general population <ref type="bibr" target="#b14">[6]</ref><ref type="bibr" target="#b15">[7]</ref><ref type="bibr" target="#b16">[8]</ref><ref type="bibr" target="#b17">[9]</ref>.</s></p><p><s>MBC is recognised as being a hormone-dependent malignancy, and it is widely accepted as an oestrogendriven disease, specifically related to hyperestrogenism <ref type="bibr" target="#b18">[10]</ref>.</s><s>In the general population, MBC is similar to lateonset, post-menopausal, oestrogen receptor-/progesterone receptor-positive (ER+/PR+) female breast cancer (FBC).</s><s>However, compared with FBC, MBC has been reported to occur later in life, present at a higher stage and display lower histologic grade, with a higher proportion of ER+ and PR+ tumours <ref type="bibr" target="#b19">[11]</ref>.</s></p><p><s>There is increasing evidence suggesting that MBC may be a group of molecularly and clinically heterogeneous malignancies which differ from those seen in women <ref type="bibr" target="#b20">[12]</ref>.</s><s>It is well known that breast cancer in women is a heterogeneous disease.</s><s>Breast cancers arising in female BRCA1 mutation carriers display characteristic pathologic features, including distinct morphology (i.e., carcinomas with medullary features) and a triple-negative phenotype [i.e., ER−, PR−, human epidermal growth factor receptor 2-negative (HER2−)] in the majority.</s><s>In contrast, BRCA2 breast tumours are a more heterogeneous group, being broadly similar to non-BRCA-associated breast tumours, which more closely resemble post-menopausal FBCs, although with a tendency to be of high grade and HER2− <ref type="bibr" target="#b21">[13]</ref>.</s></p><p><s>Current knowledge of the pathologic characteristics of breast cancers arising in male BRCA1/2 mutation carriers is limited, owing to the small number of carriers included in individual studies <ref type="bibr" target="#b22">[14]</ref><ref type="bibr" target="#b23">[15]</ref><ref type="bibr" target="#b24">[16]</ref><ref type="bibr" target="#b25">[17]</ref>.</s><s>In a study including 50 male BRCA1/2 mutation carriers, it was suggested that BRCA2 MBCs may represent a subgroup of tumours with a peculiar phenotype not identified in FBC and characterised by an aggressive biological behaviour <ref type="bibr" target="#b24">[16]</ref>.</s><s>Furthermore, in a study including 28 male BRCA1/2 mutation carriers, a possible BRCA2 phenotype characterised by micropapillary histology was suggested <ref type="bibr" target="#b25">[17]</ref>.</s><s>In other, smaller studies, BRCA2 MBCs were associated with younger age at diagnosis and positive lymph node status <ref type="bibr" target="#b22">[14,</ref><ref type="bibr" target="#b23">15]</ref>.</s></p><p><s>In this study, we report pathology data characteristics of 419 BRCA1/2 MBCs derived from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), who conducted the largest study of its kind to date.</s><s>The main objective of our study was to characterise the pathologic features of BRCA1/2 MBCs and contrast those with the characteristics of BRCA1/2 FBCs, as well as with MBCs in the general population.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CIMBA study participants</head><p><s>CIMBA collects data on male and female BRCA1 or BRCA2 pathogenic mutation carriers older than 18 years of age, with the majority recruited through cancer genetics clinics <ref type="bibr" target="#b26">[18]</ref>.</s><s>CIMBA data were submitted by 55 study groups in 24 countries based in Europe, North America and Australia.</s><s>Pathology data from MBC cases for the present analysis were collected by 35 study groups (Additional file 1).</s><s>Key variables collected for all CIMBA patients include year of birth, age at cancer diagnosis (breast, ovarian or prostate cancers), age at last observation, family membership, race and/or ethnicity and information on applicable prophylactic surgeries.</s><s>This work was restricted to male and female mutation carriers who had been diagnosed with breast cancer and were of self-reported European ancestry.</s><s>The number of male mutation carriers of non-European ancestry (2 BRCA1 and 20 BRCA2) was too small to allow a meaningful analysis.</s><s>These subjects were excluded from the analysis.</s></p><p><s>A signed informed consent form was obtained from study participants.</s><s>All participating studies were approved by local ethical review committees (Additional file 2).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Tumour pathology data</head><p><s>MBC pathology data were obtained from a range of sources, namely medical, pathology or tumour registry records and immunohistochemical staining and/or scoring of tissue microarrays (TMAs) (Additional file 3).</s><s>The data included information on ER, PR and HER2 status; morphological subtype; lymph node involvement; TNM (tumour, node, metastasis) staging; and histologic grade.</s><s>For ER, PR and HER2, status was classified as negative or positive.</s><s>The vast majority of centres employed a cut-off of either ≥10 % or ≥1 % of tumour nuclei staining positive to define ER/PR receptor positivity, which was not centrally reclassified, owing to the low proportion of records with supporting staining data (Additional file 3).</s><s>HER2 status was determined using immunohistochemistry (IHC) to detect strong complete membrane staining (with 3+ considered positive) with in situ hybridisation to detect HER2 gene amplification in equivocal cases.</s><s>Consistency checks were performed to validate receptor data against supplementary scoring information when provided.</s><s>Central pathology review was not performed.</s></p><p><s>Each carcinoma was assigned to a morphologic subgroup (ductal, lobular, medullary, other), which was confirmed using the World Health Organisation International Classification of Diseases 0 code for the classification of tumour type when present.</s><s>Lymph node status, along with the number of nodes showing metastatic carcinoma, was provided when available.</s><s>Staging data were based on the AJCC Cancer Staging Manual, Sixth Edition <ref type="bibr" target="#b27">[19]</ref>, with data provided on overall stage and its major attributes (primary tumour size, regional lymph node involvement and presence of distant metastasis).</s><s>Histologic grade was determined by local pathologists using modifications of the Scarff-Bloom-Richardson histological grading system as grade 1, 2 or 3. Pathology data for FBCs included in the study are described in detail elsewhere <ref type="bibr" target="#b21">[13]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>SEER data</head><p><s>We obtained MBC pathology data from the SEER 18 Registries Database for cases diagnosed from 1973 to 2011 <ref type="bibr" target="#b28">[20]</ref>.</s><s>For this study, we selected only male Caucasian cases diagnosed with invasive breast cancer.</s><s>For SEER cases, pathology characteristics included age at diagnosis; morphologic subgroup; tumour grade; lymph node status; adjusted stage based on the AJCC Cancer Staging Manual, Sixth Edition <ref type="bibr" target="#b27">[19]</ref>; ER, PR and HER2 status.</s><s>Tumour grade was classified as grade 1 (well differentiated), grade 2 (moderately differentiated) or grade 3 (poorly differentiated).</s></p><p><s>SEER includes unselected MBCs, most of which are of unknown BRCA1/2 mutation status.</s><s>On the basis of published data <ref type="bibr" target="#b11">[3,</ref><ref type="bibr" target="#b30">21,</ref><ref type="bibr" target="#b31">22]</ref>, about 10 % of MBC cases are expected to be due to BRCA1 or BRCA2 mutations.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical methods</head><p><s>Logistic regression was used to assess the association between pathologic characteristics and male BRCA1/2 mutation carrier status, as well as to compare pathologic characteristics with data from female BRCA1/2 mutation carriers and from male breast tumours arising in the general population using SEER data.</s><s>In the logistic regression analysis, each pathologic characteristic was treated as the explanatory variable.</s><s>The outcome variables were BRCA mutation status (BRCA1/BRCA2), sex (female/male) and carrier status (general population/BRCA1 mutation carrier and general population/BRCA2 mutation carrier), with the first term used as the reference group.</s><s>For assessment of continuous or ordered variables, such as age at diagnosis, stage and grade, tests for trend were also performed.</s></p><p><s>Analyses within CIMBA data were adjusted for age at diagnosis and country of origin, whereas comparisons between CIMBA and SEER data were adjusted only for age at diagnosis.</s><s>In addition, an adjustment for calendar year of diagnosis was included in all analyses, based on the following groupings: up to 1990, 1991-2000 and after 2000.</s><s>A robust variance approach was used to allow for dependencies between related individuals.</s><s>All analyses were carried out using Stata v13 software (StataCorp, College Station, TX, USA).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pathologic characteristics of MBC in BRCA1 and BRCA2 mutation carriers</head><p><s>Information was available for 419 MBC cases, including 375 BRCA2 and 44 BRCA1 mutation carriers (Additional file 1).</s><s>Median age at MBC diagnosis was 62 years [interquartile range (IQR) 16] for BRCA2 mutation carriers and 62 years (IQR 18) for BRCA1 mutation carriers.</s></p><p><s>The analysis was restricted to carriers diagnosed with invasive breast cancer (326 BRCA2 and 40 BRCA1) (Additional file 4).</s><s>The majority of tumours were invasive ductal carcinoma in both BRCA2 (95.1 %) and BRCA1 (100 %) carriers.</s><s>Among tumours with data on stage and grade, the majority of BRCA2 mutation carriers presented with stage 2 disease (47 %) and tumours of histologic grade 3 (56.7 %), whereas the majority of BRCA1 mutation carriers presented with stage 3-4 disease (42.9 %) and histologic grade 3 tumours (69.2 %).</s><s>Among tumours with ER, PR and HER2 data, 96.7 % were ER+, 86.8 % were PR+ and 83.4 % were HER2− in BRCA2 mutation carriers, vs. 90.3</s><s>% ER+, 78.6 % PR+ and 89.5 % HER2− in BRCA1 mutation carriers.</s></p><p><s>Age at diagnosis was inversely associated with grade in BRCA2 mutation carriers (grade 1/2 vs. grade 3, P = 0.005), with no evidence for differences in ER, PR and HER2 distributions by age (test for differences P &gt; 0.05 for all) (Fig. <ref type="figure" target="#fig_0">1</ref>).</s><s>Furthermore, there was no evidence of association between grade and ER or PR status (P values for trend = 0.50 and 0.78, respectively).</s><s>For BRCA1 mutation carriers, no differences in age-specific proportions of tumours by grade or ER, PR and HER2 status were observed, but their numbers were small (data not shown).</s></p><p><s>When we compared the pathologic characteristics of MBC in BRCA1 and BRCA2 mutation carriers, we observed no statistically significant differences.</s><s>However, tumours in BRCA1 mutation carriers were more likely to present with more advanced stage (42.9 % vs. 23.5 %, P for trend = 0.11) and were more frequently ER− (9.7 % vs. 3.3 %, P = 0.17) and PR− (21.4 % vs. 13.2 %, P = 0.27) than tumours in BRCA2 mutation carriers (Additional file 4).</s></p><p><s>Characterisation of BRCA2 MBCs: comparison with BRCA2 FBC and with MBC in the general population We evaluated possible pathologic differences between invasive breast cancers arising in male and female BRCA2 mutation carriers by comparing available data from female mutation carriers with breast cancer in the CIMBA dataset.</s><s>Data from 3750 country-matched female BRCA2 mutation carriers diagnosed with invasive breast cancer were included in this analysis (Table <ref type="table" target="#tab_0">1</ref>).</s><s>The results revealed that there were significantly fewer invasive lobular carcinomas among male BRCA2 mutation carriers than among female BRCA2 mutation carriers [odds ratio (OR) 0.14, 95 % confidence interval (CI) 0.05-0.43].</s><s>In addition, We then compared pathologic features of MBC arising in BRCA2 mutation carriers with characteristics of MBC in the general U.S. population as represented by SEER.</s><s>We extracted pathology data of 6351 men with invasive breast cancer from the SEER 18 database.</s><s>There were no statistically significant differences in pathology characteristics between MBCs arising in BRCA2 mutation carriers and those arising in the general population, with the exception of grade and lymph node status (Table <ref type="table" target="#tab_1">2</ref>).</s><s>The comparison between MBCs arising in BRCA1 mutation carriers with those of 6351 MBCs from the SEER database showed no significant differences in pathologic characteristics (Additional file 6).</s><s>However, BRCA1 male breast tumours trended toward higher grade compared with those in the general population (P for trend = 0.003).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>To date, most of the available knowledge on MBC is based on MBC arising in the general population, whose BRCA1/2 mutation status is largely unknown.</s><s>In this study, we sought to determine whether MBC arising in BRCA1 and BRCA2 mutation carriers displayed specific pathologic characteristics.</s><s>We used data on 419 MBCs with BRCA1 and BRCA2 mutations from an international consortium (CIMBA).</s><s>The CIMBA series represents the largest collection of MBCs arising in BRCA1 and BRCA2 mutation carriers to date.</s><s>In our series, the majority of MBC cases (375 of 419, 89.5 %) were BRCA2 mutation carriers, a finding which corroborates prior, smaller studies.</s></p><p><s>In this study, we conducted the first comparison of the pathologic features of breast cancer arising in male and female BRCA1/2 mutation carriers, taking advantage of the previously collected pathology data from female BRCA1/2 mutation carriers assembled by CIMBA <ref type="bibr" target="#b21">[13]</ref>.</s></p><p><s>We found that breast cancer in male BRCA2 mutation carriers was of significantly higher stage and histologic grade, and was more frequently ER+ and PR+, than breast cancer in female BRCA2 mutation carriers.</s><s>Advanced stage disease at breast cancer diagnosis is more frequently observed in men than in women <ref type="bibr" target="#b32">[23]</ref>.</s><s>In general, this is thought to reflect diagnostic delay in a population unaware of its risk and (appropriately) not encouraged to undergo routine breast cancer screening.</s><s>Furthermore, although breast cancer primaries in men tend to be slightly smaller than those in women when they are first diagnosed, they more often have locoregional metastasis at presentation.</s><s>Indeed, we found that male BRCA2 mutation carriers presented more frequently with lymph node involvement than breast cancer in female mutation carriers.</s></p><p><s>It is known that MBC presents with lower histologic grade tumours than FBC in the general population <ref type="bibr" target="#b19">[11]</ref>.</s><s>In contrast, in the present study, we showed that MBC associated with BRCA2 mutations presents with higher histologic grade than both breast cancer in female BRCA2 mutation carriers and MBC in the general population from SEER.</s></p><p><s>We observed that the majority of BRCA2 MBCs are of grades 2 and 3.</s><s>However, grade 3 tumours were more frequent among male BRCA2 mutation carriers diagnosed at younger ages (younger than age 50 years) than among those diagnosed at older ages, whereas grade 2 tumours showed an inverse trend.</s><s>Age-specific proportions of MBCs stratified by grade show that grade 3 significantly decreased with increasing age in male BRCA2 mutation carriers.</s><s>These results may indicate that young male BRCA2 mutation carriers could be susceptible to more aggressive (i.e., high-grade) breast cancer.</s><s>Differences in grade among male breast carcinomas by age may be an indicator of a biologic complexity in MBC, as suggested in FBC <ref type="bibr" target="#b33">[24]</ref>.</s></p><p><s>In a previous, single-country case series, MBCs associated with BRCA2 mutations were found to be of higher grade than non-BRCA2 MBC <ref type="bibr" target="#b24">[16]</ref>.</s><s>In the present study, we confirmed this association in a large, multicentre series and showed that this association was age-specific.</s><s>The identification of a specific BRCA2-associated phenotype suggestive of an aggressive behaviour might define a subset of MBC patients (i.e., patients with high-grade breast tumours and with young age at diagnosis) who may particularly benefit from adjuvant chemotherapy <ref type="bibr" target="#b10">[2,</ref><ref type="bibr" target="#b34">25]</ref>.</s></p><p><s>We also showed that high-grade breast tumours were more likely to arise in male than in female BRCA2 mutation carriers, indicating that BRCA2 mutations might be associated with different breast cancer phenotypes in men and in women.</s><s>It has been suggested that high grade is a surrogate for proliferation, and, although the evidence is conflicting, this may add to the understanding of the molecular differences of MBC and FBC.</s></p><p><s>MBC is recognised as being primarily a hormonedependent malignancy, and, in general, MBC is described as being more frequently ER+ and PR+ than FBC <ref type="bibr" target="#b18">[10,</ref><ref type="bibr" target="#b19">11,</ref><ref type="bibr" target="#b32">23]</ref>.</s><s>In the present study, we showed that BRCA2 MBCs are more likely than BRCA2 FBCs to be ER+ and PR+, thus suggesting that susceptibility to hereditary breast cancer may be influenced by differences in hormonal background between male and female BRCA2 mutation carriers.</s></p><p><s>Invasive lobular carcinomas are very rare in men, accounting for only about 2 % of all MBCs <ref type="bibr" target="#b32">[23,</ref><ref type="bibr" target="#b35">26]</ref>.</s><s>We also found significantly fewer lobular carcinomas among male than female BRCA2 mutation carriers.</s><s>However, it is worth noting that breast cancers in female BRCA2 mutation carriers frequently show a lobular morphology <ref type="bibr" target="#b21">[13]</ref>, thus suggesting differences in the pathogenic mechanisms of male and female BRCA2 breast cancer.</s></p><p><s>The number of MBC cases with BRCA1 mutations in our datasets was much smaller than the number of BRCA2 mutation carriers, and our results in this subset of patients should therefore be interpreted with caution.</s><s>We found that BRCA1 MBC cases were of significantly higher stage, and more frequently ER+ and PR+, than BRCA1 FBCs.</s><s>Despite the small sample size, our results suggest that hormone receptor pathways also are a driving force in BRCA1 MBC.</s><s>It is well known that most of the breast tumours arising in female BRCA1 mutation carriers tend to be ER− and PR−, with a small percentage being ER + <ref type="bibr" target="#b21">[13,</ref><ref type="bibr" target="#b36">27,</ref><ref type="bibr" target="#b37">28]</ref>.</s><s>Given that both ER− and ER+ BRCA1 breast cancers seem to originate from a common luminal progenitor cell population, it has been suggested that ER status of breast cancer occurring in BRCA1 mutation carriers may be under control of different molecular mechanisms <ref type="bibr" target="#b38">[29]</ref>.</s><s>The finding that MBCs associated with BRCA1 mutations are frequently ER+ suggests that the hormonal milieu may be a mechanism controlling ER status in BRCA1 tumours.</s><s>The different hormonal background between males and females and the absence of hormone exposures related to reproductive history in males as compared with FBC may also influence biologic and molecular mechanisms underlying the pathologic differences between MBC and FBC.</s><s>Following the findings in the present study, future studies are warranted which focus on the comprehensive somatic and molecular profiling of MBC and FBC in mutation carriers.</s><s>Such studies could provide new insights into the complex nature of the origin and evolution of MBC and FBC.</s></p><p><s>Interestingly, we found no statistically significant differences in the pathologic characteristics between MBCs in BRCA1/2 mutation carriers and those in the general population, with the exception of histologic grade.</s><s>Male BRCA2 mutation carriers more frequently have grade 2/3 vs. grade 1 tumours, compared with the large, unselected population of MBC cases from SEER.</s><s>A similar trend also was observed for BRCA1 mutation carriers.</s><s>These findings suggest that, although MBCs arising in male BRCA1/2 mutation carriers seem to be very similar to MBCs arising in the general population, according to morphologic and immunophenotypic features, they represent a subgroup characterised by aggressive biology.</s></p><p><s>The importance of histologic grade as a prognostic factor in breast cancer has been ascertained in FBC <ref type="bibr" target="#b39">[30]</ref>.</s></p><p><s>Recent data indicate that high-grade tumours are associated with shorter disease-free survival and overall survival rates in MBC patients <ref type="bibr" target="#b34">[25]</ref>.</s><s>Thus, on the basis of our results, we can suggest that BRCA2 MBC may display an aggressive phenotype and possibly a more unfavourable prognosis.</s><s>This is a question in need of additional survival data that we are planning to collect within CIMBA.</s></p><p><s>In this study, tumour pathology data were collected through several mechanisms, including medical records, pathology reports and TMAs.</s><s>Given the global distribution of CIMBA study sites, central pathology review was not feasible.</s><s>Laboratory methods for tissue preparation, IHC, biochemical assays, scoring systems and data interpretation vary widely (Additional file 3), and misclassifications cannot be excluded.</s><s>Unfortunately, details of hormone receptor scoring for all mutation carriers were not available to standardise definitions across centres.</s><s>However, data collected by CIMBA are more representative of typical assessment of pathology conducted in routine practice, and the distributions of hormone receptors' status across different study centres and countries in CIMBA were generally consistent.</s><s>There was some variation in the distribution of some variables, including ER status, probably due to changing assay thresholds and detection methods over time and from country to country.</s><s>Therefore, adjustments based on calendar year of diagnosis and country of origin were included for all analyses.</s><s>Missing data for some variables, including HER2 status, and the very small number of male BRCA1 mutation carriers in the study may have impacted the statistical power to detect associations.</s></p><p><s>CIMBA collects data only on BRCA1 and BRCA2 mutation carriers.</s><s>Therefore, to compare the tumour characteristics of MBC from the general population, we took advantage of the publicly available SEER data <ref type="bibr" target="#b28">[20]</ref>.</s><s>Although the U.S. SEER program is the largest source of epidemiologic information on the incidence and survival rates of cancer, it includes data from a single country, and this represents a limitation when attempting to generalise our findings to what one would expect in a collaborative international consortium.</s><s>However, results from this study, based on a large, multicentre series, replicated previous findings of much smaller studies carried out in single populations <ref type="bibr" target="#b22">[14]</ref><ref type="bibr" target="#b23">[15]</ref><ref type="bibr" target="#b24">[16]</ref><ref type="bibr" target="#b25">[17]</ref>, providing some reassurance that our results were not biased by the different selection of cases in SEER and in CIMBA.</s><s>In addition, SEER includes MBCs that were not screened for BRCA1 and BRCA2 mutations, and it can be expected that about 10 % of those cases <ref type="bibr" target="#b11">[3,</ref><ref type="bibr" target="#b30">21,</ref><ref type="bibr" target="#b31">22]</ref> may be due to BRCA1 or BRCA2 mutations.</s><s>In future studies, researchers should aim to compare BRCA1/2 MBC cases with those known not to have BRCA1/2 mutations.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions</head><p><s>Analysing the largest series of BRCA1 and BRCA2 breast cancers collected to date from both sexes, we have demonstrated that breast tumours arising in BRCA1 and BRCA2 mutation carriers display pathologic differences between males and females.</s><s>Thus, our results add to the accumulating evidence that breast cancer may not be the same disease in both genders <ref type="bibr" target="#b20">[12]</ref> and suggest that the heritable influence on breast cancer susceptibility may be context-dependent, perhaps influenced by the microenvironment (i.e., a different hormonal milieu in males and females).</s></p><p><s>Moreover, we identified a specific BRCA2-associated MBC phenotype characterised by higher histologic grade compared with both BRCA2 FBC and MBC from a general population.</s><s>This raises the possibility that BRCA2 MBC may be more aggressive than its sporadic counterpart.</s></p><p><s>Overall, our findings could lead to the eventual development of clinical strategies appropriate for MBC management, and of gender-specific risk prediction models that might guide more targeted screening and surveillance programs for male mutation carriers.</s></p><p><s>of the National Cancer Institute, NIH, and by support services contracts</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1</head><label>1</label><figDesc><div><p><s>Fig. 1 Age-specific proportion of BRCA2 (breast cancer 2, early onset gene) male breast cancers according to pathologic characteristics.</s><s>a Grade.</s><s>b Oestrogen receptor (ER) status.</s><s>c Progesterone receptor (PR) status.</s><s>d Human epidermal growth factor receptor 2 (HER2) status.</s><s>Error bars represent confidence intervals associated with each proportion</s></p></div></figDesc><graphic coords="4,63.84,365.56,467.66,327.52" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Pathology of invasive BRCA2 female and male breast tumours and ORs in predicting male BRCA2 mutation carrier status BRCA2 MBCs were of significantly higher stage (P for trend = 2.14 × 10 −5 ) and higher grade (P for trend = 0.005), presented more frequently with lymph node involvement (OR 1.55, 95 % CI 1.12-2.14)</s><s>and were more likely to be ER+ (OR 10.</s></p></div></figDesc><table><row><cell></cell><cell>Females</cell><cell></cell><cell>Males</cell><cell></cell><cell>Unadjusted OR (95 % CI)</cell><cell>Adjusted OR a (95 % CI)</cell></row><row><cell></cell><cell>Number</cell><cell>Percent</cell><cell>Number</cell><cell>Percent</cell><cell></cell><cell></cell></row><row><cell>Total b</cell><cell>3750</cell><cell></cell><cell>326</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Morphology</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Ductal carcinoma</cell><cell>2693</cell><cell>83.6</cell><cell>253</cell><cell>95.1</cell><cell>Reference</cell><cell>Reference</cell></row><row><cell>Lobular carcinoma</cell><cell>276</cell><cell>8.6</cell><cell>4</cell><cell>1.5</cell><cell>0.15 (0.06-0.41)</cell><cell>0.14 (0.05-0.43)</cell></row><row><cell>Medullary carcinoma</cell><cell>60</cell><cell>1.9</cell><cell>2</cell><cell>0.8</cell><cell>0.35 (0.09-1.46)</cell><cell>0.46 (0.10-2.11)</cell></row><row><cell>Other</cell><cell>193</cell><cell>6.0</cell><cell>7</cell><cell>2.6</cell><cell>0.39 (0.18-0.83)</cell><cell>0.54 (0.24-1.23)</cell></row><row><cell>TNM stage</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>0-1</cell><cell>560</cell><cell>40.2</cell><cell>44</cell><cell>29.5</cell><cell>Reference</cell><cell>Reference</cell></row><row><cell>2</cell><cell>629</cell><cell>45.1</cell><cell>70</cell><cell>47.0</cell><cell>1.42 (0.95-2.10)</cell><cell>1.97 (1.20-3.23)</cell></row><row><cell>3-4</cell><cell>205</cell><cell>14.7</cell><cell>35</cell><cell>23.5</cell><cell>2.17 (1.37-3.44)</cell><cell>3.55 (1.96-6.44)</cell></row><row><cell>Histologic grade</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Grade 1</cell><cell>149</cell><cell>5.9</cell><cell>8</cell><cell>3.5</cell><cell>Reference</cell><cell>Reference</cell></row><row><cell>Grade 2</cell><cell>1057</cell><cell>41.7</cell><cell>92</cell><cell>39.8</cell><cell>1.62 (0.77-3.41)</cell><cell>1.88 (0.76-4.67)</cell></row><row><cell>Grade 3</cell><cell>1329</cell><cell>52.4</cell><cell>131</cell><cell>56.7</cell><cell>1.84 (0.88-3.83</cell><cell>2.66 (1.08-6.55)</cell></row><row><cell>Lymph node status</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Negative</cell><cell>1398</cell><cell>52.4</cell><cell>123</cell><cell>50.2</cell><cell>Reference</cell><cell>Reference</cell></row><row><cell>Positive</cell><cell>1270</cell><cell>47.6</cell><cell>122</cell><cell>49.8</cell><cell>1.09 (0.84-1.43)</cell><cell>1.55 (1.12-2.14)</cell></row><row><cell>ER status</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Negative</cell><cell>650</cell><cell>22.7</cell><cell>8</cell><cell>3.3</cell><cell>Reference</cell><cell>Reference</cell></row><row><cell>Positive</cell><cell>2211</cell><cell>77.3</cell><cell>236</cell><cell>96.7</cell><cell>8.67 (4.26-17.66)</cell><cell>10.59 (5.15-21.80)</cell></row><row><cell>PR status</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Negative</cell><cell>892</cell><cell>35.0</cell><cell>30</cell><cell>13.2</cell><cell>Reference</cell><cell>Reference</cell></row><row><cell>Positive</cell><cell>1654</cell><cell>65.0</cell><cell>198</cell><cell>86.8</cell><cell>3.56 (2.41-5.26)</cell><cell>5.04 (3.17-8.04)</cell></row><row><cell>HER2 status</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Negative</cell><cell>1404</cell><cell>85.9</cell><cell>126</cell><cell>83.4</cell><cell>Reference</cell><cell>Reference</cell></row><row><cell>Positive</cell><cell>230</cell><cell>14.1</cell><cell>25</cell><cell>16.6</cell><cell>1.21 (0.77-1.90)</cell><cell>1.22 (0.70-2.11)</cell></row><row><cell>Subtypes</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>ER+ and/or PR+, HER2−</cell><cell>1112</cell><cell>69.8</cell><cell>118</cell><cell>81.9</cell><cell>Reference</cell><cell>Reference</cell></row><row><cell>ER+ and/or PR+, HER2+</cell><cell>182</cell><cell>11.4</cell><cell>22</cell><cell>15.3</cell><cell>1.14 (0.70-1.84)</cell><cell>1.18 (0.65-2.13)</cell></row><row><cell>ER−, PR−, HER2+</cell><cell>40</cell><cell>2.5</cell><cell>2</cell><cell>1.4</cell><cell>0.47 (0.11-1.98)</cell><cell>0.42 (0.09-1.98)</cell></row><row><cell>Triple-negative (ER−, PR−, HER2−)</cell><cell>260</cell><cell>16.3</cell><cell>2</cell><cell>1.4</cell><cell>0.07 (0.02-0.30)</cell><cell>0.05 (0.01-0.22)</cell></row><row><cell>ER+ and/or PR+, HER2− vs. others</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>0.51 (0.33-0.79)</cell><cell>0.42 (0.25-0.70)</cell></row></table><note><p><s>BRCA2 breast cancer 2, early onset gene, CI confidence interval, ER oestrogen receptor, HER2 human epidermal growth factor receptor 2, OR odds ratio, PR progesterone receptor, TNM tumour, node, metastasis Significant results are indicated by boldface type a Analyses adjusted for country, age at diagnosis and calendar year of diagnosis b Some data for each pathologic feature are not available compared with BRCA2 FBCs,</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc><div><p><s>Pathology of invasive MBCs in the general population from SEER and BRCA2 MBCs and ORs in predicting male BRCA2 mutation carrier status</s></p></div></figDesc><table><row><cell></cell><cell>SEER</cell><cell></cell><cell>BRCA2 carriers</cell><cell></cell><cell>Unadjusted OR (95 % CI)</cell><cell>Adjusted OR a (95 % CI)</cell></row><row><cell></cell><cell>Number</cell><cell>Percent</cell><cell>Number</cell><cell>Percent</cell><cell></cell><cell></cell></row><row><cell>Total b</cell><cell>6351</cell><cell></cell><cell>326</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Morphology</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Ductal carcinoma</cell><cell>5265</cell><cell>86.2</cell><cell>253</cell><cell>95.1</cell><cell>Reference</cell><cell>Reference</cell></row><row><cell>Lobular carcinoma</cell><cell>82</cell><cell>1.5</cell><cell>4</cell><cell>1.5</cell><cell>1.02 (0.37-2.79)</cell><cell>1.00 (0.36-2.74)</cell></row><row><cell>Medullary Carcinoma</cell><cell>16</cell><cell>0.3</cell><cell>2</cell><cell>0.8</cell><cell>2.60 (0.59-11.38)</cell><cell>2.34 (0.52-10.39)</cell></row><row><cell>TNM stage</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>0-1</cell><cell>1699</cell><cell>34.9</cell><cell>44</cell><cell>29.5</cell><cell>Reference</cell><cell>Reference</cell></row><row><cell>2</cell><cell>1990</cell><cell>40.9</cell><cell>70</cell><cell>47.0</cell><cell>1.36 (0.93.-1.99)</cell><cell>1.37 (0.93-2.01)</cell></row><row><cell>3-4</cell><cell>1181</cell><cell>24.2</cell><cell>35</cell><cell>23.5</cell><cell>1.14 (0.73-1.77)</cell><cell>1.11 (0.72-1.73)</cell></row><row><cell>Histologic grade</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Grade 1</cell><cell>632</cell><cell>12.9</cell><cell>8</cell><cell>3.5</cell><cell>Reference</cell><cell>Reference</cell></row><row><cell>Grade 2</cell><cell>2432</cell><cell>49.7</cell><cell>92</cell><cell>39.8</cell><cell>2.99 (1.44-6.19)</cell><cell>2.98 (1.44-6.19)</cell></row><row><cell>Grade 3</cell><cell>1834</cell><cell>37.4</cell><cell>131</cell><cell>56.7</cell><cell>5.64 (2.75-11.60)</cell><cell>5.53 (2.69-11.39)</cell></row><row><cell>Lymph node status</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Negative</cell><cell>2773</cell><cell>58.0</cell><cell>123</cell><cell>50.2</cell><cell>Reference</cell><cell>Reference</cell></row><row><cell>Positive</cell><cell>2009</cell><cell>42.0</cell><cell>122</cell><cell>49.8</cell><cell>1.37 (1.05-1.78)</cell><cell>1.28 (0.98-1.67)</cell></row><row><cell>ER status</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Negative</cell><cell>229</cell><cell>5.3</cell><cell>8</cell><cell>3.3</cell><cell>Reference</cell><cell>Reference</cell></row><row><cell>Positive</cell><cell>4064</cell><cell>94.7</cell><cell>236</cell><cell>96.7</cell><cell>1.66 (0.81-3.41)</cell><cell>1.95 (0.93-4.06)</cell></row><row><cell>PR status</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Negative</cell><cell>627</cell><cell>15.0</cell><cell>30</cell><cell>13.2</cell><cell>Reference</cell><cell>Reference</cell></row><row><cell>Positive</cell><cell>3562</cell><cell>85.0</cell><cell>198</cell><cell>86.8</cell><cell>1.16 (0.79-1.72)</cell><cell>1.30 (0.88-1.92)</cell></row><row><cell>HER2 status</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Negative</cell><cell>627</cell><cell>87.8</cell><cell>126</cell><cell>83.4</cell><cell>Reference</cell><cell>Reference</cell></row><row><cell>Positive</cell><cell>87</cell><cell>12.2</cell><cell>25</cell><cell>16.6</cell><cell>1.43 (0.88-2.32)</cell><cell>1.30 (0.79-2.13)</cell></row><row><cell>Subtypes</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>ER+ and/or PR+, HER2−</cell><cell>608</cell><cell>87.5</cell><cell>118</cell><cell>81.9</cell><cell>Reference</cell><cell>Reference</cell></row><row><cell>ER+ and/or PR+, HER2+</cell><cell>80</cell><cell>11.5</cell><cell>22</cell><cell>15.3</cell><cell>1.42 (0.85-2.36)</cell><cell>1.28 (0.76-2.17)</cell></row><row><cell>ER−, PR−, HER2+</cell><cell>7</cell><cell>1.0</cell><cell>2</cell><cell>1.4</cell><cell>1.47 (0.30-7.18)</cell><cell>1.09 (0.22-5.45)</cell></row><row><cell>Triple-negative (ER−, PR−, HER2−)</cell><cell>0</cell><cell>0.0</cell><cell>2</cell><cell>1.4</cell><cell>-</cell><cell>-</cell></row><row><cell>ER+ and/or PR+, HER2− vs. others</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>1.54 (0.95-2.49)</cell><cell>1.38 (0.84-2.27)</cell></row></table><note><p><s>BRCA2 breast cancer 2, early onset gene, CI confidence interval, ER oestrogen receptor, HER2 human epidermal growth factor receptor 2, OR odds ratio, PR progesterone receptor, TNM tumour, node, metastasis Significant results are indicated by boldface type a Analyses adjusted for age at diagnosis and calendar year of diagnosis b Some data for each pathologic feature are not available</s></p></note></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Acknowledgements BCFR: This work was supported by grant UM1 CA164920 from the National Cancer Institute.</s><s>The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centres in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government or the BCFR.</s><s>BCFR-AU: Acknowledge Maggie Angelakos, Judi Maskiell, Gillian Dite and Helen Tsimiklis.</s><s>BCFR-NY: We thank members and participants in the New York site of the Breast Cancer Family Registry for their contributions to the study.</s><s>BCFR-ON: We thank members and participants in the Ontario Familial Breast Cancer Registry for their contributions to the study.</s><s>BFBOCC-LT is partly supported by Research Council of Lithuania grant LIG-07/2012.</s><s>We acknowledge Vilius Rudaitis and Laimonas Griškevičius.</s><s>BIDMC is supported by the Breast Cancer Research Foundation.</s><s>BRICOH: SLN was partially supported by the Morris and Horowitz Families Endowed Professorship.</s><s>CBCS: This work was supported by the NEYE Foundation.</s><s>CNIO: This work was partially supported by Spanish Association against Cancer (AECC08), RTICC 06/0020/1060, FISPI08/1120, Mutua Madrileña Foundation (FMMA) and SAF2010-20493.</s><s>We thank Alicia Barroso, Rosario Alonso and Guillermo Pita for their assistance.</s><s>COH-CCGCRN: City of Hope Clinical Cancer Genetics Community Network and the Hereditary Cancer Research Registry, supported in part by award number RC4CA153828 (JNW, principal investigator) from the National Cancer Institute and the Office of the Director, National Institutes of Health.</s><s>The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</s><s>CONSIT TEAM: Funds from Italian citizens who allocated the 5 × 1000 share of their tax payment in support of the Fondazione IRCCS Istituto Nazionale Tumori, according to Italian laws (INT institutional strategic projects '5 × 1000') to SM and from FiorGen Foundation for Pharmacogenomics to LP. LO is supported by AIRC (IG12780).</s><s>VS is supported by FIRC (triennial fellowship "Mario e Valeria Rindi").</s><s>We acknowledge Maria Grazia Tibiletti of the OIO is an American Cancer Society clinical research professor.</s><s>We thank Cecilia Zvocec, Qun Niu, physicians, genetic counsellors, research nurses and staff of the Cancer Risk Clinic for their contributions to this resource, and the many families who contribute to our program.</s><s>UCSF Cancer Risk Program and Helen Diller Family Comprehensive Cancer Center.</s><s>We thank the following genetic counsellors for participant recruitment: Beth Crawford, Kate Loranger, Julie Mak, Nicola Stewart, Robin Lee, Amie Blanco and Peggy Conrad.</s><s>Thanks are also extended to Ms. Salina Chan for her data management.</s><s>UKFOCR was supported by a project grant from CRUK to Paul Pharoah.</s><s>We thank Paul Pharoah, Simon Gayther, Susan Ramus, Carole Pye, Patricia Harrington and Eva Wozniak for their contributions to the UKFOCR.</s><s>University of Pennsylvania: National Institutes of Health (NIH) (grants R01-CA102776 and R01-CA083855); Breast Cancer Research Foundation; Susan G. Komen Foundation for the Cure, Basser Research Center for BRCA.</s><s>UPITT/MWH: Frieda G. and Saul F. Shapira BRCA-Associated Cancer Research Program; Hackers for Hope Pittsburgh.</s><s>VFCTG: Victorian Cancer Agency, Cancer Australia, National Breast Cancer Foundation Geoffrey Lindeman, Marion Harris, Martin Delatycki of the Victorian Familial Cancer Trials Group.</s><s>We thank Sarah Sawyer and Rebecca Driessen for assembling this data and Ella Thompson for performing all DNA amplification.</s><s>WCP: BYK is funded by the American Cancer Society Early Detection Professorship (SIOP-06-258-01-COUN) and National Center for Advancing Translational Sciences (NCATS) grant UL1TR000124.</s><s>Funding for the iCOGS infrastructure came from: the European Community's Seventh Framework Programme under grant agreement number 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C1281/ A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 -the GAME-ON Initiative), the U.S. Department of Defense (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation and the Ovarian Cancer Research Fund.</s><s>The funders had no role in the design and conduct of the study; collection, management, analysis and interpretation of data; preparation, review or approval of the manuscript; or the decision to submit the manuscript for publication.</s><s>Comprehensive Cancer Center, Georgetown University, Washington, DC, USA. 63</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Additional files</head><p><s>Abbreviations BC: breast cancer; BRCA1: breast cancer 1, early onset gene; BRCA2: breast cancer 2, early onset gene; CI: confidence interval; CIMBA: Consortium of Investigators of Modifiers of BRCA1/2; ER: oestrogen receptor; FBC: female breast cancer; HER2: human epidermal growth factor receptor 2; IHC: immunohistochemistry; IQR: interquartile range; MBC: male breast cancer; OR: odds ratio; PR: progesterone receptor; SEER: Surveillance, Epidemiology, and End Results; TMA: tissue microarray; TNM: tumour, node, metastasis.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Competing interests</head><p><s>The authors declare that they have no competing interests.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Authors' contributions</head><p><s>Conception and design: ACA and LO.</s><s>Acquisition of data: AMM, SLN, SF, BYK, GM, PJ, DLT, KKZ, NJC, KLN, SMD, TRR, SJR, RLN, OIO, JR, SY, MAC, LS, AB, ISP, MT, UBJ, AET, LS, ILA, GG, PJH, ENI, MHG, PLM, CFS, CR, GK, JV, KO, MR, AL, LJ, EM, LF, MN, PV, FJC, EH, KJR, PS, SK, kConFab, MRT, PP, MM, LM, AA, OTJ, RBB, AJ, JL, AI, MAP, JB, OD, EO, JP, GI, AK, HEBON, HN, KA, PPS, TC, TVM, BP, KBMC, CI, CE, CL, DS, LB, MB, AM, AG, CS, CE, DN, DS, EH, KK, NA, RV, DW, AKG, DGE, DF, JP, JA, LI, RP, RE, SE, EMBRACE, UH, JG, FF, GF, BP, GG, PR, AR, LC, LP, LV, DP, IZ, AS, PR, SM, BP, MB, BB, AV, VP, ST, PP, JNW, AO, JB, LMG, SH, AG, BE, TVOH, LS, YCD, NT, RJ, DEG, SSB, MBD, AB, MBT, EMJ, MS, DFE and GCT.</s><s>Analysis and interpretation of data: VS, DB, ACA and LO.</s><s>Writing of the manuscript: VS, DB, AMM, SLN, SF, ACA and LO.</s><s>All authors read and approved the final manuscript.</s><s>(CA116201), a U.S. Department of Defense Ovarian Cancer Idea award (W81XWH-10-1-0341), a grant from the Breast Cancer Research Foundation, a generous gift from the David F. and Margaret T. Grohne Family Foundation and the Ting Tsung and Wei Fong Chao Foundation.</s><s>MODSQUAD was supported by MH CZ -DRO (MMCI, 00209805) and by the European Regional Development Fund and the State Budget of the Czech Republic (RECAMO, CZ.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">We thank all the GEMO collaborating groups for their contribution to this study. GEMO Collaborating Centers are Coordinating Centres: Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon -Centre Léon Bérard, &amp; Equipe «Génétique du cancer du sein</title>
	</analytic>
	<monogr>
		<title level="m">of Hereditary Breast and Ovarian Cancer (GC-HBOC) is supported by the German Cancer Aid (grant 110837 to Rita K. Schmutzler) and by the Center for Molecular Medicine Cologne (CMMC)</title>
		<title level="s">Laurent Castera. Institut Paoli Calmettes</title>
		<editor>
			<persName><forename type="first">Yves-Jean</forename><surname>Bignon</surname></persName>
		</editor>
		<meeting><address><addrLine>France; Paris; Villejuif; Olivier Caron, Marine Guillaud-Bataille. Centre Jean Perrin, Clermont-Ferrand; Lyon; Caen; Marseille; Bourdon; Montpellier</addrLine></address></meeting>
		<imprint>
			<publisher>Pascal Pujol</publisher>
		</imprint>
		<respStmt>
			<orgName>Centre de Recherche en Cancérologie de Lyon ; CHU Arnaud-de-Villeneuve</orgName>
		</respStmt>
	</monogr>
	<note type="report_type">Brigitte Bressac-de-Paillerets</note>
	<note>Pascaline Berthet. Tetsuro Noguchi, Audrey Remenieras, François Eisinger</note>
</biblStruct>

<biblStruct xml:id="b1">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Oscar</forename><surname>Centre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lille: Jean-Philippe</forename><surname>Lambret</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Joëlle</forename><surname>Peyrat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Françoise</forename><surname>Fournier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Philippe</forename><surname>Révillion</surname></persName>
		</author>
		<author>
			<persName><forename type="first">†</forename><surname>Vennin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Claude</forename><forename type="middle">Adenis</forename><surname>Centre Paul</surname></persName>
		</author>
		<author>
			<persName><surname>Strauss</surname></persName>
		</author>
		<editor>Marc Frénay. CHU Limoges: Laurence Vénat-Bouvet</editor>
		<imprint>
			<pubPlace>Strasbourg; Bordeaux; Chambéry; Nice</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Groupe</forename><surname>Hospitalier Pitié-Salpétrière</surname></persName>
		</author>
		<editor>Henry T. Lynch, Carrie L</editor>
		<imprint>
			<pubPlace>Paris; Omaha, NE, USA</pubPlace>
		</imprint>
		<respStmt>
			<orgName>Alexandre Damette. Creighton University</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<monogr>
		<title level="m" type="main">University: CI received support from the Non-Therapeutic Subject Registry Shared Resource at Georgetown University (NIH/NCI grant P30-CA051008), the Fisher Center for Familial Cancer Research, and Swing for the Cure. G-FAST: Kim De Leeneer is supported by GOA grant</title>
		<author>
			<persName><surname>Snyder</surname></persName>
		</author>
		<author>
			<persName><surname>Georgetown</surname></persName>
		</author>
		<idno>BOF10/GOA/019</idno>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">103 Clinical Cancer Genetics, City of Hope Clinical Cancer Genetics Community Research Network</title>
		<author>
			<persName><surname>Isciii (spain</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">partially supported by European Regional Development FEDER funds. We acknowledge Alicia Tosar for her technical assistance. HEBCS was financially Unit of Medical Genetics, Department of Preventive and Predictive Medicine</title>
				<meeting><address><addrLine>Milan, Italy; Milan, Italy; Aviano, PN, Italy.; Milan, Italy; Milan, Italy; Bari, Italy; Duarte, CA, USA</addrLine></address></meeting>
		<imprint>
			<biblScope unit="volume">101</biblScope>
		</imprint>
		<respStmt>
			<orgName>CRO Aviano National Cancer Institute</orgName>
		</respStmt>
	</monogr>
	<note>Human Cancer Genetics Program. Spanish National Cancer Centre (CNIO</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<author>
			<persName><forename type="first">Spain</forename><surname>Madrid</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">105 Biomedical Network on Rare Diseases (CIBERER)</title>
				<meeting><address><addrLine>Madrid, Spain</addrLine></address></meeting>
		<imprint>
			<biblScope unit="volume">106</biblScope>
		</imprint>
		<respStmt>
			<orgName>Spanish National Cancer Centre (CNIO</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<monogr>
		<title level="m" type="main">Human Genotyping (CEGEN) Unit, Human Cancer Genetics Program</title>
		<author>
			<persName><forename type="first">Spain</forename><surname>Madrid</surname></persName>
		</author>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<pubPlace>Spanish National Cancer Research Centre (CNIO), Madrid, Spain</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<monogr>
		<title level="m" type="main">Cancer Division</title>
		<imprint>
			<pubPlace>Copenhagen, Denmark; Copenhagen, Denmark</pubPlace>
		</imprint>
		<respStmt>
			<orgName>QIMR Berghofer Medical Research Institute, Brisbane, Australia. 109 Department of Clinical Genetics, Rigshospitalet, Copenhagen University Hospital ; 110 Department of Oncology, Rigshospitalet, Copenhagen University Hospital</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<monogr>
		<title level="m" type="main">117 Department of Pathology &amp; Molecular Medicine, Juravinski Hospital and Cancer Centre</title>
		<imprint>
			<publisher>Mailman School of Public Health</publisher>
			<pubPlace>Boston, MA, USA; Salt Lake City, UT, USA; Salt Lake City, UT, USA; Fox Chase Cancer Center, Philadelphia, PA, USA; Hamilton, ON, Canada; New York, NY, USA; Fremont, CA, USA; Parkville, Australia</pubPlace>
		</imprint>
		<respStmt>
			<orgName>Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. 112 Department of Medical Oncology, Beth Israel Deaconess Medical Center ; 113 State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania. 114 Department of Dermatology, Huntsman Cancer Institute, University of Utah School of Medicine ; University of Utah School of Medicine ; McMaster University ; Columbia University ; 119 Department of Epidemiology, Cancer Prevention Institute of California ; 120 Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne</orgName>
		</respStmt>
	</monogr>
	<note>118 Department of Epidemiology</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">An international comparison of male and female breast cancer incidence rates</title>
		<author>
			<persName><forename type="first">D</forename><surname>Ly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Forman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ferlay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Brinton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Cook</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cancer</title>
		<imprint>
			<biblScope unit="volume">132</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1918" to="1926" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Multidisciplinary meeting on male breast cancer: summary and research recommendations</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Korde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Zujewski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Kamin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Giordano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Domchek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">F</forename><surname>Anderson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="2114" to="2122" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">BRCA1 and BRCA2 mutations in a population-based study of male breast cancer</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">M</forename><surname>Basham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Lipscombe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Ward</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Gayther</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Ponder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Easton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Breast Cancer Res</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page">R2</biblScope>
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy</title>
		<author>
			<persName><forename type="first">L</forename><surname>Ottini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Masala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>'amico</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mancini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Saieva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Aceto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="342" to="347" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Male breast cancer: genetics, epigenetics, and ethical aspects</title>
		<author>
			<persName><forename type="first">P</forename><surname>Rizzolo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Silvestri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tommasi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Pinto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Danza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Falchetti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="75" to="82" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers</title>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="issue">15</biblScope>
			<biblScope unit="page" from="1310" to="1316" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Breast Cancer Linkage Consortium. Cancer incidence in BRCA1 mutation carriers</title>
		<author>
			<persName><forename type="first">D</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Easton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="issue">18</biblScope>
			<biblScope unit="page" from="1358" to="1365" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Breast cancer risk among male BRCA1 and BRCA2 mutation carriers</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">C</forename><surname>Tai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Domchek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Parmigiani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="issue">23</biblScope>
			<biblScope unit="page" from="1811" to="1814" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Risk of breast cancer in male BRCA2 carriers</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Evans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Susnerwala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dawson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Woodward</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Maher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Lalloo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Med Genet</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="710" to="711" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Prediagnostic sex steroid hormones in relation to male breast cancer risk</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Brinton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Key</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">N</forename><surname>Kolonel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">B</forename><surname>Michels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">D</forename><surname>Sesso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ursin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="issue">18</biblScope>
			<biblScope unit="page" from="2041" to="2050" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Male breast cancer: a populationbased comparison with female breast cancer</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">F</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Jatoi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Rosenberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="232" to="239" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Molecular profiling of male breast cancer -lost in translation?</title>
		<author>
			<persName><forename type="first">I</forename><surname>Johansson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Killander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Linderholm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Hedenfalk</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Biochem Cell Biol</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="526" to="535" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)</title>
		<author>
			<persName><forename type="first">N</forename><surname>Mavaddat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Barrowdale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">L</forename><surname>Andrulis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Domchek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Eccles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Nevanlinna</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Epidemiol Biomarkers Prev</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="134" to="147" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients</title>
		<author>
			<persName><forename type="first">E</forename><surname>Kwiatkowska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Teresiak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Filas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Karczewska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Breborowicz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mackiewicz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="4452" to="4459" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">C</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Steele</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Kuan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Greilac</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Neuhausen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Breast Cancer Res Treat</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="771" to="778" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in Italy</title>
		<author>
			<persName><forename type="first">L</forename><surname>Ottini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Silvestri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Rizzolo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Falchetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Zanna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Saieva</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Breast Cancer Res Treat</title>
		<imprint>
			<biblScope unit="volume">134</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="411" to="418" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas</title>
		<author>
			<persName><forename type="first">S</forename><surname>Deb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jene</forename><forename type="middle">N</forename><surname>Kconfab Investigators</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Fox</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Cancer</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">510</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA)</title>
		<author>
			<persName><forename type="first">G</forename><surname>Chenevix-Trench</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Milne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Antoniou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Couch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Easton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Goldgar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Breast Cancer Res</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">104</biblScope>
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<monogr>
		<author>
			<persName><forename type="first">S</forename><surname>Edge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Byrd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Compton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Fritz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Greene</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Trotti</surname></persName>
		</author>
		<title level="m">AJCC cancer staging manual</title>
				<meeting><address><addrLine>New York</addrLine></address></meeting>
		<imprint>
			<publisher>Springer</publisher>
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note>6th ed</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Counties. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Prevention Sciences, Surveillance Research Program, Surveillance Systems Branch</title>
	</analytic>
	<monogr>
		<title level="m">Linked to County Attributes -Total</title>
				<meeting><address><addrLine>U.S.</addrLine></address></meeting>
		<imprint>
			<date type="published" when="1969">November 2013 Submission (1973-2011. 1969-2012. April 2014</date>
		</imprint>
		<respStmt>
			<orgName>U.S. Department of Health and Human Services, National Cancer Institute</orgName>
		</respStmt>
	</monogr>
	<note>Surveillance, Epidemiology, and End Results (SEER) Program. Incidence -SEER 18 Registries Research Data + Hurricane Katrina Impacted Louisiana Cases. released. updated 7 May 2014</note>
</biblStruct>

<biblStruct xml:id="b29">
	<monogr>
		<title level="m" type="main">Accessed 22</title>
		<imprint>
			<date type="published" when="2016-01">January 2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">S</forename><surname>Friedman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Gayther</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kurosaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Gordon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Noble</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Casey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Hum Genet</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="313" to="319" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">BRCA1/ BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in central Italy</title>
		<author>
			<persName><forename type="first">L</forename><surname>Ottini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Rizzolo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Zanna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Falchetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Masala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ceccarelli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Breast Cancer Res Treat</title>
		<imprint>
			<biblScope unit="volume">116</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="577" to="586" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Breast carcinoma in men: a population-based study</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Giordano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">U</forename><surname>Buzdar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Perkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">N</forename><surname>Hortobagyi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="51" to="57" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes?</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">K</forename><surname>Anders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Parker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Carey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Blackwell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Klauber-Demore</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="e18" to="20" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Clinicopathological and immunohistochemical characteristics in male breast cancer: a retrospective case series</title>
		<author>
			<persName><forename type="first">G</forename><surname>Masci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Caruso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Caruso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Salvini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Carnaghi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Giordano</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncologist</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="586" to="592" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Characterizing lobular carcinoma of the male breast using the SEER database</title>
		<author>
			<persName><forename type="first">A</forename><surname>Moten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Obirieze</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">L</forename><surname>Wilson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Surg Res</title>
		<imprint>
			<biblScope unit="volume">185</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="e71" to="76" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Estrogen receptor status in BRCA1-and BRCA2-related breast cancer: the influence of age, grade, and histological type</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">D</forename><surname>Foulkes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Metcalfe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">M</forename><surname>Hanna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">T</forename><surname>Lynch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ghadirian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="2029" to="2034" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Pathologic features and immunophenotype of estrogen receptor-positive breast cancers in BRCA1 mutation carriers</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Kaplan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Schnitt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Collins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Garber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Montgomery</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Surg Pathol</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1483" to="1488" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers</title>
		<author>
			<persName><forename type="first">E</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Vaillant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Forrest</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Pal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Hart</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Med</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="907" to="913" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Breast cancer prognostic classification in the molecular era: the role of histological grade</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Rakha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Reis-Filho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Baehner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Dabbs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Decker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Eusebi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Breast Cancer Res</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">207</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
